Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 3
1981 3
1982 1
1984 3
1985 1
1986 2
1987 3
1988 2
1989 2
1990 3
1991 1
1993 1
1995 1
1996 2
1998 1
2000 2
2001 1
2002 1
2003 1
2004 1
2005 1
2009 2
2012 1
2015 1
2016 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

41 results
Results by year
Filters applied: . Clear all
Page 1
Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J, Gupta S, Herzyk D, Hurst C, Ivens IA, Kawabata T, Maier C, Mounho B, Rup B, Shankar G, Smith H, Thomas P, Wierda D. Ponce R, et al. Among authors: wierda d. Regul Toxicol Pharmacol. 2009 Jul;54(2):164-82. doi: 10.1016/j.yrtph.2009.03.012. Epub 2009 Apr 2. Regul Toxicol Pharmacol. 2009. PMID: 19345250
Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluations.
Komocsar WJ, Blackbourne JL, Halstead CA, Winstead CJ, Wierda D. Komocsar WJ, et al. Among authors: wierda d. J Immunotoxicol. 2016;13(1):7-19. doi: 10.3109/1547691X.2014.994793. Epub 2015 Sep 4. J Immunotoxicol. 2016. PMID: 25585959
Safety evaluation of immunomodulatory biopharmaceuticals: can we improve the predictive value of preclinical studies?
Black LE, Green JD, Rener J, Dayan A, Cavagnaro JA, Spindler P, Bussiere JL, Bouchard P, Inoue T, Thomas PT, Essayan DM, Gillett NA, Hart TK, Hastings K, House RV, Latta D, Liminga U, Treacy G, Wierda D. Black LE, et al. Among authors: wierda d. Hum Exp Toxicol. 2000 Apr;19(4):205-7. doi: 10.1191/096032700678815855. Hum Exp Toxicol. 2000. PMID: 10918508 No abstract available.
41 results